University Hospitals Bristol and Weston NHS Foundation Trust

Freedom of Information Request Ref: 22-742

5 January 2023

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we do hold the information you are requesting

Patients with acute myeloid leukaemia (AML)

1. How many patients have received treatment with venetoclax for AML during the past 24 months? Note: please provide data for the most recent 24-month period available via your prescribing/management system.
Answer: 8

2. What is the average daily dose (mg) for AML patients receiving venetoclax during the past 24 months?
Answer:
Please note, the Trust does not hold the data in a format that would enable us to fully respond to your request to the level of detail required and a manual trawl for this information would significantly exceed the 18 hours limit set down by the FOI as the reasonable limit. Section 12 of the FOIA provides that we are not obliged to spend in excess of 18 hours in any sixty-day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

3. What is the average cycle intensity (days) for AML patients receiving venetoclax during the past 24 months? (e.g., 14-day cycles, 21-day cycles, other length of cycle)
Answer:
Please note, the Trust does not hold the data in a format that would enable us to fully respond to your request to the level of detail required and a manual trawl for this information would significantly exceed the 18 hours limit set down by the FOI as the reasonable limit. Section 12 of the FOIA provides that we are not obliged to spend in excess of 18 hours in any sixty-day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

4. What is the average duration of treatment (months) for AML patients receiving venetoclax during the past 24 months?
Answer:
Please note, the Trust does not hold the data in a format that would enable us to fully respond to your request to the level of detail required and a manual trawl for this information would significantly exceed the 18 hours limit set down by the FOI as the reasonable limit. Section 12 of the FOIA provides that we are not obliged to spend in excess of 18 hours in any sixty-day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

Patients with chronic lymphocytic leukaemia (CLL)

5. Please complete the table below based on the number of patients that have received venetoclax in each of the specified regimens for CLL in the last 24 months.
Note: please provide data for the most recent 24-month period available via your prescribing/management system.

	Treatment regimens		
	Venetoclax + obinutuzumab	**Venetoclax + rituximab**	**Venetoclax monotherapy**
Total number of CLL patients receiving this treatment regimen during the past 24 months	18	16	7
Average daily maintenance dose (mg) of venetoclax for patients initiated on this regimen during the past 24 months*			
Average duration (months) of venetoclax treatment for patients initiated on this regimen during the past 24 months			

Please note, regarding average daily maintenance dose and average duration of treatment, the Trust does not hold the data in a format that would enable us to fully respond to your request to the level of detail required and a manual trawl for this information would significantly exceed the 18 hours limit set down by the FOI as the reasonable limit. Section 12 of the FOIA provides that we are not obliged to spend in excess of 18 hours in any sixty-day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

***We would like to understand the average daily dose of venetoclax in CLL patients during maintenance treatment i.e. after the initial 8-week period during which patients would be receiving a titration regimen.**
Patients with acute myeloid leukaemia (AML) or chronic lymphocytic leukaemia (CLL)

6. Please complete the table below with the average number of venetoclax 10 mg x 14 tablet packs† used per AML or CLL patient receiving each of the specified regimens during the past 24 months.

	AML treatment regimen	CLL treatment regimens		
	Venetoclax + azacitidine	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Average number of venetoclax 10 mg x 14 tablet packs used per patient in each treatment regimen during the past 24 months				

There are five different pack sizes of venetoclax available in the UK:
Pack 1: venetoclax 10 mg x 14 tablets
Pack 2: venetoclax 50 mg x 7 tablets
Pack 3: venetoclax 100 mg x 7 tablets
Pack 4: venetoclax 100 mg x 14 tablets
Pack 5: venetoclax 100 mg x 112 tablets

Please note, the Trust does not hold the data in a format that would enable us to fully respond to your request to the level of detail required and a manual trawl for this information would significantly exceed the 18 hours limit set down by the FOI as the reasonable limit. Section 12 of the FOIA provides that we are not obliged to spend in excess of 18 hours in any sixty-day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

7. Please can you share your prescribing protocol(s) for venetoclax in AML and CLL?
Answer: We follow SWAG cancer alliance protocols which can be found here: **Protocols Archive - SWAG Cancer Alliance**

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Data Protection Officer
University Hospitals Bristol and Weston NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click here.

Yours sincerely

Freedom of Information Team
University Hospitals Bristol and Weston NHS Foundation Trust